How to Write Aggregate Safety Reports

Learn how experienced aggregate physicians evaluate evidence, communicate uncertainty and prepare scientifically robust aggregate safety reports.

How to Write Aggregate Safety Reports

Introduction

Aggregate safety reports represent the highest level of pharmacovigilance assessment. Unlike individual case review, aggregate reporting requires reviewers to integrate diverse sources of evidence, evaluate scientific uncertainty and determine whether the cumulative understanding of a medicinal product has changed over time.

Although different report types have different regulatory objectives, they share common scientific principles. Experienced aggregate physicians therefore apply a consistent approach regardless of whether they are preparing a PBRER, DSUR, PADER or another aggregate report.

This article introduces those universal principles.


The Purpose of Aggregate Reports

Aggregate reports are not collections of safety information.

They are scientific evaluations.

Their purpose is to explain:

The emphasis should always remain on interpretation rather than description.


The Four Levels of Pharmacovigilance Thinking

Every aggregate report should progress through four distinct stages.

Level 1 — Observation

What happened?

Examples include:


Level 2 — Interpretation

What do the observations mean?

The reviewer evaluates:


Level 3 — Knowledge Evolution

What has changed since the previous assessment?

This is the question that distinguishes aggregate reporting from routine pharmacovigilance.

The reviewer evaluates whether cumulative knowledge has evolved.


Level 4 — Regulatory Action

Does the new understanding require action?

Possible consequences include:


The Regulatory Chain of Reasoning

Every conclusion within an aggregate report should be traceable through a logical chain of scientific reasoning.

Individual Cases

↓

Cumulative Data

↓

Signal Detection

↓

Signal Evaluation

↓

Risk Evaluation

↓

Integrated Benefit-Risk Evaluation

↓

Overall Conclusion

↓

Regulatory Actions

↓

Product Information

↓

Risk Management

No regulatory action should exist without supporting scientific evidence.

Likewise, every important scientific conclusion should be traceable back to objective data.

Last reviewed: 2026-06-30